Abstract: Isocitrate dehydrogenase 1 (IDH1), a key ratelimiting enzyme in tricarboxylic acid cycle, is found within the cytoplasm and peroxisomes. In recent years, IDH1 mutation is discovered in most glioma and its large scale metabolites, 2hydroxyglutarate, may be involved in tumor as potential carcinogens, and is shown to be closely related to better patients′ survival as well. IDH1 mutation is anticipated to be a novel genetic biomarker which will guide the treatments of clinical glioma.

Key words: Isocitrate dehydrogenase 1, Mutation, Glioma, Tumor markers, biological, Prognosis